Stag2 Deficiency Reprograms GATA1 Binding, Driving Dyserythropoiesis in Myelodysplastic Syndromes

Unraveling Dyserythropoiesis in Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders defined by ineffective hematopoiesis, cytopenias, and risk of progression to acute myeloid leukemia [1, 2]. While modern classification systems incorporate molecular data to refine prognosis [3, 4], the precise mechanisms driving the hallmark dyserythropoiesis remain a significant clinical challenge [5]. The discovery of recurrent mutations in epigenetic regulators like TET2 and Stag2 has focused attention on how alterations in chromatin, the structural packaging of DNA, contribute to disease pathogenesis [6, 7]. A recent study provides a mechanistic link, investigating how mutations in Stag2 can hijack a key transcription factor, leading to the specific patterns of aberrant blood cell production seen in MDS [8, 9].

Stag2 Mutations and Hematopoietic Fate

The development of distinct blood cell lineages is a tightly regulated process. The transcription factor GATA1 is a master regulator with pleiotropic functions, meaning it directs the development of multiple cell types, particularly red blood cells (erythroid lineage) and platelet-producing megakaryocytes. How GATA1 orchestrates these divergent fates has been a long-standing question. This study explored the role of Stag2, a protein that is frequently mutated in MDS and myeloid leukemia of Down Syndrome. Stag2 is a component of the cohesin complex, a molecular machine responsible for organizing and maintaining the three-dimensional structure of chromosomes. Because this structure dictates which genes are physically accessible to transcription factors, the researchers hypothesized that Stag2 loss alters chromatin accessibility, thereby determining where GATA1 can bind to DNA and which cellular fate it promotes.

Murine Model Reveals Dysregulated Erythropoiesis

To test their hypothesis, the investigators developed a murine model with a deleted Stag2 gene (Stag2∆) to observe the effects on blood cell formation in a living system. The results painted a clear picture of hematopoietic skewing. The Stag2-deficient mice exhibited a reduced number of erythroid progenitors (EryPs), the precursor cells committed to the red blood cell lineage. Furthermore, these progenitors showed impaired terminal erythroid differentiation, a failure to mature into functional red blood cells, which directly reflects the anemia common in MDS. In a stark contrast, the same mice showed an increased number of megakaryocyte progenitors (MkPs) and a subsequent increase in mature megakaryocytes. Together, these findings demonstrate that the loss of Stag2 redirects hematopoietic output, suppressing the erythroid lineage while promoting the megakaryocytic lineage.

Chromatin Remodeling Reprograms GATA1 Activity

To understand the molecular basis for this lineage skewing, the researchers analyzed the erythroid progenitors from the Stag2∆ mice. Using RNA-sequencing to measure gene activity and ATAC-sequencing to map chromatin accessibility (regions of DNA that are open and available for transcription), they found that Stag2 deficiency rewired the genetic program. The analysis revealed a loss of expression of erythroid target genes alongside a gain of expression of megakaryocyte target genes. Critically, the total amount of the GATA1 protein itself was unchanged. This suggested the problem was not a lack of GATA1, but a misdirection of its activity. Indeed, further analysis confirmed that Gata1 occupancy, which refers to the specific sites on the genome where the factor binds, was reprogrammed from erythroid to megakaryocyte gene targets. This retargeting was associated with the enrichment of Fli1 motifs, which are DNA binding sequences for the Fli1 transcription factor, a known driver of megakaryopoiesis. This suggests that in the absence of Stag2, the chromatin landscape changes, causing GATA1 to bind to new sites, often near Fli1, thereby activating a megakaryocytic program instead of its normal erythroid one.

Functional Consequences and Therapeutic Implications

The molecular reprogramming observed in the mouse model had direct functional consequences. Using orthogonal differentiation assays, which test a cell's developmental potential in a controlled laboratory setting, the researchers confirmed that Stag2-deficient erythroid progenitors had diminished erythroid output and augmented megakaryocyte output. This finding provides functional proof that the loss of Stag2 actively drives cells away from the red blood cell fate. In a clinically relevant experiment, the researchers found this lineage skewing was partially reversed with Fli1 knockdown, a technique that reduces the expression of the Fli1 protein. This implicates Fli1 as a key accomplice in GATA1's misdirection and identifies it as a potential therapeutic target for correcting dyserythropoiesis. Crucially, the study established the direct relevance of these findings to human disease, demonstrating that human models and primary cells from MDS patients recapitulated the essential phenotypic and molecular features of the murine model. This confirmation provides confidence that the mechanism is not an artifact of the animal model but a core driver of human MDS.

Clinical Significance: A Mechanism for MDS Dyserythropoiesis

This study establishes a clear mechanistic principle: chromatin accessibility is a primary determinant of transcription factor binding specificity. For the clinician, this translates a complex concept into a tangible explanation for disease. It shows that the physical state of DNA, governed by proteins like Stag2, dictates which genetic programs are executed. The research uncovers an accessibility-driven Gata1 retargeting mechanism as a direct cause of MDS dyserythropoiesis. In Stag2-deficient cells, GATA1 is hijacked, abandoning its role in erythropoiesis to instead promote megakaryopoiesis, leading to the anemia and cytopenias seen in patients. This detailed molecular understanding, including the role of Fli1 in mediating this effect, moves the field beyond descriptive pathology. It provides a rationale for developing diagnostics to identify patients with this specific defect and raises the possibility of future therapies aimed at correcting GATA1's mis-targeting to restore balanced blood cell production.

References

1. Arber DA, Orazi A, Hasserjian RP, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016. doi:10.1182/blood-2016-03-643544

2. Khoury JD, Solary É, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022. doi:10.1038/s41375-022-01613-1

3. Döhner H, Estey EH, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016. doi:10.1182/blood-2016-08-733196

4. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009. doi:10.1182/blood-2009-03-209262

5. Thomas W, Hinchliffe RF, Briggs C, Macdougall IC, Littlewood T, Cavill I. Guideline for the laboratory diagnosis of functional iron deficiency. British Journal of Haematology. 2013. doi:10.1111/bjh.12311

6. Sudunagunta VS, Stewart EM, Chen Y, et al. Stag2 dependent chromatin remodeling enforces the erythroid-specific Gata1 cistrome.. Blood. 2026. doi:10.1182/blood.2025030554

7. Delhommeau F, Dupont S, Valle VD, et al. Mutation in TET2 in Myeloid Cancers. New England Journal of Medicine. 2009. doi:10.1056/nejmoa0810069

8. Xie X, Yu T, Li X, et al. Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials. Signal Transduction and Targeted Therapy. 2023. doi:10.1038/s41392-023-01589-z

9. Shi Z, Pang K, Wu Z, et al. Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. Signal Transduction and Targeted Therapy. 2023. doi:10.1038/s41392-023-01383-x